NFE2L2 and cancer: Notably, mutations in the KEAP1-NRF2 system, often seen in cancer, result in an abnormal constitutive activation of the pathway, leading to overexpression of downstream genes which confers resistance to chemotherapy through protection towards oxidative and electrophilic stress, causing the cancer cells to acquire malignancy and increased survival10,12–17.